Expert describes usage of ArteraAI Prostate Test

In this video, Rana R. McKay, MD, shares her experience with the ArteraAI Prostate Test. McKay is a medical oncologist and associate professor of medicine at the University of California, San Diego.

Transcription:

How does the ArteraAI Prostate Test compare with other prognostic tools in prostate cancer?

It hasn't necessarily been compared head to head against other platforms such as Decipher or other prognostic instruments. But compared to what we utilize largely right now in the clinic is clinical parameters to help guide risk stratification. And it definitely adds to the clinical parameters, the NCCN criteria that are already used for guiding risk assessment, it definitely adds to that, beyond just what the clinical parameters do. The clinical parameters themselves are not predictive; they're just prognostic, and the platform does have the capacity to also inform prediction of response to ADT.

Please describe your own experience with the ArteraAI Prostate Test.

Where I have found that it has been incredibly useful has been in those unfavorable intermediate-risk patients or those individuals who are kind of borderline at the risk spectrum. And I think it's really important to understand, what is their risk of recurrence, to help guide clinical decision-making and what is the likelihood that they're going to respond to therapy, to ADT. For individuals that have high-risk disease, for example, duration of therapy matters, and potency of ADT matters. So I think we're going to continue to learn more about this test as it gets applied in clinical practice. And additionally, we'll learn more as additional clinical trials implement this assay to inform outcomes.

Is there anything you would like to add?

I think maybe the only other thing to add is, while there have been studies that have validated ArteraAI in the prostate cancer realm, there's great opportunity for potential application across other solid tumor malignancies and other genitourinary malignancies, including bladder and kidney cancer. So, particularly in the localized setting as you're informing decisions around perioperative therapy, adjuvant therapy, and conducting risk assessments. So I think that's something to look forward to in the future.

This transcript was edited for clarity.